 Patients will continue VPA daily during maintenance therapy. All patients will start bevacizumab, 10 mgkg by vein every two weeks, at the start of maintenance therapy. Maintenance therapy will continue uninterrupted if all laboratory tests continue to meet on-study criteria. In the absence of unacceptable toxicity or disease progression, patients will continue to receive protocol treatment for a maximum total duration of two years including the radiation phase. 